Involving Electroporation Patents (Class 435/461)
  • Patent number: 12055556
    Abstract: A manipulation system includes a sample stage configured such that a minute object is placed thereon, a first manipulator including a first pipette for holding the minute object, a second manipulator including a second pipette for manipulating the minute object that is held to the first pipette, an imaging unit configured to image the minute object, and a control unit configured to control the sample stage, the first pipette, the second pipette, and the imaging unit. The control unit moves the second pipette to a direction approaching the sample stage from the upper side of the minute object, at a position where the second pipette overlaps with the minute object and is away from the center of the minute object in a direction orthogonal to the extending direction of the second pipette, when viewed from the direction perpendicular to the sample stage.
    Type: Grant
    Filed: May 27, 2019
    Date of Patent: August 6, 2024
    Assignee: NSK LTD.
    Inventors: Hiroki Ueda, Manabu Kishida, Nobuaki Takana
  • Patent number: 11661595
    Abstract: Disclosed is a device for applying an electric field to a suspension of cells, comprising at least one chamber which comprises at least one internal space (40) for holding the suspension, the internal space (40) comprising at least two segments (41, 42), wherein each segment (41, 42) comprises at least one electrode (43, 44) and wherein neighboring electrodes (43, 44) are separated from each other by at least one gap (47) which is at least partially filled with an insulating material (46), and wherein the edges of the electrodes (43, 44) facing each other within the internal space (40) are rounded. Rounding the electrodes' edges facing a neighboring electrode results in a significant reduction of field gradients and thus even of the risk of arcing. Also disclosed is a method in which voltage is applied to at least one active electrode (43, 44) while the electrodes (43, 44, 45) or electrode segments next and/or opposite to the active electrode (43, 44) are set to ground potential.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 30, 2023
    Assignee: Lonza Cologne GmbH
    Inventors: Ludger Altrogge, Timo Gleissner, Andreas Heinze, Sven Hermsmeier
  • Patent number: 11492609
    Abstract: A well for electrically stimulating at least one cell. The well includes a bottom portion and comprises an adaptive electrode arrangement for introducing an electric field into the well. The adaptive electrode arrangement includes a pair of electrodes disposed within the well. Each electrode of the pair of electrodes has a distal end and is independently and axially displaceable relative to the other electrode and the bottom portion of the well. The distal end of each electrode of the pair of electrodes is in contact with the bottom portion of the well, ensuring a uniform and constant electric field is applied within the well.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: November 8, 2022
    Assignee: AMGEN INC.
    Inventors: Chuck Z. Li, Brandon Zachary Sarich, Phillip Ng
  • Patent number: 11426728
    Abstract: An electroporation device is disclosed, which includes a first tubular electrode including a first inlet and a first outlet; an aqueous solution supply connected to the first tubular electrode and configured for supplying an aqueous solution to the first tubular electrode and for allowing a droplet of the aqueous solution to be discharged from the first outlet of the first tubular electrode, the aqueous solution contains a cell and a delivery target substance; a second tubular electrode including a second inlet and a second outlet, wherein the second inlet is spaced away from the first outlet at a spacing corresponding to a size of a portion of the droplet; a power supply for applying a voltage to the electrodes for electroporation of the cell in the droplet; and a droplet sucking unit connected to the second electrode and configured for allowing the droplet to be sucked into the second electrode.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 30, 2022
    Assignee: PUKYONG NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Do Jin Im, Myung Mo Ahn, Byeong Sun Yoo
  • Patent number: 11420204
    Abstract: Provided herein are devices, systems, and methods for analysis of objects, such as cells. The devices, systems, and methods organize a plurality of objects in a plurality of partitions by trapping an object in a trap and transferring the object to an adjacent partition. The devices, systems, and methods provide for parallel analysis of a plurality of objects.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: August 23, 2022
    Assignee: Duke University
    Inventors: Benjamin B. Yellen, Roozbeh Abedini-Nassab, Korine A. Ohiri, David M. Murdoch, Kris Wood
  • Patent number: 11098352
    Abstract: The invention discloses diagnostic techniques based on single cell genomics, consisting of obtaining a blood sample, enriching a sub-population of cells present in the blood sample, sequestering individual cells or group of cells from the blood sample, obtaining sequencing data from the sequestered cells or group of cells, using genetic variant information to determine the provenance of the cells, and genetically analyzing the cells of the correct provenance to provide a diagnostic readout. Using the cell-based testing techniques of the invention, the number of false positives is greatly reduced when compared to cell-free DNA (cfDNA) based traditional testing techniques. The invention may be effectively employed for non-invasive prenatal (NIPT) diagnostics, oncological testing and other diagnostic procedures.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: August 24, 2021
    Assignee: Fluxion Biosciences, Inc.
    Inventors: Cristian Ionescu-Zanetti, Jeff Jensen, Michael Schwartz
  • Patent number: 10538728
    Abstract: Provided is a bubble-jetting member, the tip section of which is not damaged even when high voltage is applied thereto. There can be provided a bubble jetting member comprising: a core that is formed of a conductive material; a shell part that is formed of an insulating material, includes an extended section that extends beyond the tip of the core, and is closely adhered at least partially to the core and covers the core; and a space that is formed between the extended section and the tip of the core and has a bubble-jetting port, wherein there is formed on the tip of the extended section a thick portion that is thicker than the rest of the extended section whereby the tip section is not damaged.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: January 21, 2020
    Assignee: Japan Science and Technology Agency
    Inventors: Yoko Yamanishi, Kazuki Takahashi, Shun Omi
  • Patent number: 10427292
    Abstract: The invention relates to a positioning device (120, 154), for example for testing, comprising a micromechanical positioning actuator (130) for causing movement of a probe (150, 151) with respect to a target (110), a positioning controller (145), the positioning controller (145) having an output coupled to the actuator (130) for controlling the movement, and the positioning controller (145) having a steering input (156) for receiving a steering signal to the positioning controller (145), and the positioning controller (145) arranged to control the movement based on the steering signal. The measurement device may have memory for storing positioning control instructions (300). The positioning controller (145) may be arranged to control said movement based on said steering signal and said positioning control instructions (300).
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: October 1, 2019
    Assignee: Sensapex Oy
    Inventors: Mikko Vähäsöyrinki, Markku Vimpari
  • Patent number: 10167502
    Abstract: The invention discloses diagnostic techniques based on single cell genomics, consisting of obtaining a blood sample, enriching a sub-population of cells present in the blood sample, sequestering individual cells or group of cells from the blood sample, obtaining sequencing data from the sequestered cells or group of cells, using genetic variant information to determine the provenance of the cells, and genetically analyzing the cells of the correct provenance to provide a diagnostic readout. Using the cell-based testing techniques of the invention, the number of false positives is greatly reduced when compared to cell-free DNA (cfDNA) based traditional testing techniques. The invention may be effectively employed for non-invasive prenatal (NIPT) diagnostics, oncological testing and other diagnostic procedures.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: January 1, 2019
    Assignee: Fluxion Biosciences, Inc.
    Inventors: Cristian Ionescu-Zanetti, Jeff Jensen, Michael Schwartz
  • Patent number: 10143759
    Abstract: A method of treating cancerous tumors is presented herein. The method includes injecting an effective dose of a plasmid encoded for IL-12, B7-1 or IL-15 into a cancerous tumor and subsequently administering at least one high voltage, short duration pulse to the tumor. The electroporation pulses may be administered at at least 700V/cm for a duration of less than 1 millisecond. The intratumor treatments with electroporation may be administered in at least a two-treatment protocol with the time between treatments being about 7 days. The intratumor treatments with electroporation may be administered in a three-treatment protocol with a time of four days between the first and second treatments and a time of three days between the second and third treatments. It was found that the intratumor treatments using electroporation not only resulted in tumor regression but also induced an immune memory response which prevented the formation of new tumors.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: December 4, 2018
    Assignee: University of South Florida
    Inventors: Richard Heller, Kenneth E. Ugen
  • Patent number: 9662488
    Abstract: Systems and methods are provided for migrating cells implanted or endogenous in tissue. The system may include first and second delivery electrodes configured for insertion in tissue and a direct current (DC) power source operatively coupled to the first and second delivery electrodes. The system further may include a programmable controller operatively coupled to the DC power source, wherein the programmable controller is programmed to direct the DC power source to deliver an electric field between the first delivery electrode and the second delivery electrode at a stimulation to nonstimulation ratio sufficient to cause the cells to migrate within tissue selectively.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: May 30, 2017
    Assignee: The Regents of the University of California
    Inventors: Min Zhao, Junfeng Feng, Lei Zhang
  • Patent number: 9610364
    Abstract: A method of treating cancerous tumors is presented herein. The method includes injecting an effective dose of a plasmid encoded for IL-12, B7-1 or IL-15 into a cancerous tumor and subsequently administering at least one high voltage, short duration pulse to the tumor. The electroporation pulses may be administered at at least 700V/cm for a duration of less than 1 millisecond. The intratumor treatments with electroporation may be administered in at least a two-treatment protocol with the time between treatments being about 7 days. The intratumor treatments with electroporation may be administered in a three-treatment protocol with a time of four days between the first and second treatments and a time of three days between the second and third treatments. It was found that the intratumor treatments using electroporation not only resulted in tumor regression but also induced an immune memory response which prevented the formation of new tumors.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: April 4, 2017
    Assignee: University of South Florida
    Inventors: Richard Heller, Melinda Lee Lucas, Loree C. Heller
  • Patent number: 9533138
    Abstract: Provided is a method of transfecting cells of the cochlea with an agent by electroporation, and in certain embodiments using a cochlear implant to provide at least one electroporation electrode.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: January 3, 2017
    Assignee: NewSouth Innovations Pty Limited
    Inventor: Gary David Housley
  • Patent number: 9352002
    Abstract: Methods for promoting angiogenesis comprising administering platelet-rich plasma to a site and stimulating the site with an electromagnetic field. Platelets include platelet-rich plasma and compositions can further include stem cells such as adipose stromal cells and cells derived from bone marrow aspirate. Methods also comprise isolating platelets from a patient's blood, forming a composition including the platelets, delivering the composition to a site in need of treatment, and electrically stimulating the site.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: May 31, 2016
    Assignee: BIOMET BIOLOGICS, LLC
    Inventors: Joel C. Higgins, Bruce Simon, Jennifer E. Woodell-May
  • Publication number: 20150132269
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Inventors: Stuart H. Orkin, Andreas Reik, Fyodor Urnov
  • Patent number: 9029109
    Abstract: A system and method include delivering cells of interest to multiple traps via a channel connecting the traps, maintaining a vortex flow in the traps to trap the cells of interest in the traps, providing first molecules of interest to the traps, and providing an electric field across the traps to perform electroporation of the first molecules of interest into the cells of interest in the traps.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: May 12, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Soojung Claire Hur, Hoyoung Yun
  • Patent number: 9018013
    Abstract: The present invention provides compositions and methods for the genetic manipulation of Algal cells. The compositions and methods allow enhanced transfer of genetic material into Algal cells and the cloning and selection of genetically modified cells. Expression of proteins encoded by the genetic material will be enhanced by the methods and compositions of the invention.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: April 28, 2015
    Assignee: Life Technologies Corporation
    Inventors: Farzad Haerizadeh, Todd Peterson, Wen Chen, Ewa Lis
  • Publication number: 20150057340
    Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. It also discloses its use for the preparation of a pharmaceutical composition, e.g. for use in gene therapy, particularly in the treatment of diseases which are in need of a treatment with a therapeutic peptide or protein, preferably as defined herein.
    Type: Application
    Filed: February 15, 2013
    Publication date: February 26, 2015
    Applicant: CureVac GMBH
    Inventors: Andreas Thess, Thomas Schlake, Jochen Probst
  • Publication number: 20150056226
    Abstract: The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy.
    Type: Application
    Filed: September 8, 2014
    Publication date: February 26, 2015
    Inventor: Tai-Gyu KIM
  • Patent number: 8961994
    Abstract: Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: February 24, 2015
    Assignee: VGX Pharmaceuticals, LLC
    Inventors: Mathura P. Ramanathan, Niranjan Y Sardesai
  • Publication number: 20150037435
    Abstract: Provided are a culture medium of an adipose-derived stem cell, a method for preparing the same, and a composition for promoting hair growth, in which the composition includes the culture medium. The adipose-derived stem cell (ADSC-T) according to the present invention exhibits long lifespan, improved cell proliferation rate, and extended proliferation period, as compared with a primary adipose-derived stem cell (ADSC), and thus, the adipose-derived stem cell (ADSC-T) can be usefully used for the study about the adipose-derived stem cell and the mass production of the culture medium of the adipose-derived stem cell. In addition, according to the present invention, the culture medium of the adipose-derived stem cell (ADSC-T) that expresses a T antigen of SV40 exhibits excellent hair growth effectiveness and can be usefully used as a raw material for the hair loss prevention and hair growing agents.
    Type: Application
    Filed: August 29, 2012
    Publication date: February 5, 2015
    Inventors: Dong Wan Kim, Mi Jung Seo, Gwang Lee, Woo Hong Joo, Sun Hee Kim
  • Publication number: 20150017136
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 15, 2015
    Applicant: CELLECTIS
    Inventors: ROMAN GALETTO, AGNÈS GOUBLE, STÉPHANIE GROSSE, CÉCILE MANNIOUI, LAURENT POIROT, ANDREW SCHARENBERG, JULIANNE SMITH
  • Patent number: 8927518
    Abstract: A method of treating cancerous tumors is presented herein. The method includes injecting an effective dose of a plasmid encoded for IL-12, B7-1 or IL-15 into a cancerous tumor and subsequently administering at least one high voltage, short duration pulse to the tumor. The electroporation pulses may be administered at at least 700V/cm for a duration of less than 1 millisecond. The intratumor treatments with electroporation may be administered in at least a two-treatment protocol with the time between treatments being about 7 days. The intratumor treatments with electroporation may be administered in a three-treatment protocol with a time of four days between the first and second treatments and a time of three days between the second and third treatments. It was found that the intratumor treatments using electroporation not only resulted in tumor regression but also induced an immune memory response which prevented the formation of new tumors.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: January 6, 2015
    Assignee: University of South Florida
    Inventors: Richard Heller, Kenneth E. Ugen
  • Patent number: 8921092
    Abstract: A system and method are described for electroporating a sample that utilizes one or more sets of electrodes that are spaced apart in order to hold a surface tension constrained sample between the electrodes. The first electrode is connected to the lower body of the system while the second electrode is connected to the upper body. Both electrodes are connected to a pulse generator. Each electrode has a sample contact surface such that the first electrode and the second electrode may be positioned to hold a surface tension constrained sample between the two sample contact surfaces and the sample may receive a selected electric pulse.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: December 30, 2014
    Assignee: Applied Biosystems LLC
    Inventors: Richard Jarvis, Mike Byrom, Dmitriy Ovcharenko
  • Publication number: 20140273229
    Abstract: Embodiments of the present disclosure provide a multistage procedure for treatment of biological samples (e.g., living cells with membranes, and the like) with a substance (e.g., a drug, DNA, RNA, plasmids, and other biomolecules or materials) to achieve more efficacious intracellular delivery and transfection.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: John Mark Meacham, Kiran Durvasula, Andrei G. Fedorov, Fahrettin Levent Degertekin, Akash Mehta
  • Publication number: 20140256047
    Abstract: A simple and low cost method of producing sealed arrays of laterally ordered nanochannels interconnected to microchannels of tunable size, over large surface areas, is disclosed. The method incorporates DNA combing and subsequent imprinting. Associated micro and macroscale inlets and outlets can be formed in the same process or manufactured later in low cost, non-cleanroom techniques. The techniques embrace two procedures, generating DNA nanostrands and translating these strands into nanoscale constructs via imprinting. Devices incorporating the novel arrays have a first microchannel, a second microchannel and a nanochannel that is substantially linear and which defines an axis. The nanochannel is connected at its open ends to the microchannels, which are aligned along the axis. Methods for precise dose delivery of agents into cells employing the devices in nanoelectroporation methods are also disclosed.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Inventors: Ly James Lee, Pouyan E. Boukany, Jingjiao Guan, Nan-Rong Chiou
  • Patent number: 8822222
    Abstract: A method and apparatus are provided for delivering an agent into a cell through the application of nanosecond pulse electric fields (“nsPEF's”). The method includes circuitry for delivery of an agent into a cell via known methods followed by the application of nanosecond pulse electric fields to said cell in order to facilitate entry of the agent into the nucleus of the cell. In a preferred embodiment, the present invention is directed to a method of enhancing gene expression in a cell comprising the application of nanosecond pulse electric fields to said cell. An apparatus for generating long and short pulses according to the present invention is also provided. The apparatus includes a pulse generator capable of producing a first pulse having a long duration and low voltage amplitude and a second pulse having a short duration and high voltage amplitude.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: September 2, 2014
    Assignees: Eastern Virginia Medical School, Old Dominion University
    Inventors: Stephen J. Beebe, Karl H. Schoenbach, Richard Heller
  • Patent number: 8822223
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: September 2, 2014
    Assignee: Argos Therapeutics, Inc.
    Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
  • Publication number: 20140242155
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Application
    Filed: February 22, 2014
    Publication date: August 28, 2014
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
  • Patent number: 8802643
    Abstract: A method of treating cancerous tumors is presented herein. The method includes injecting an effective dose of a plasmid encoded for IL-12, B7-1 or IL-15 into a cancerous tumor and subsequently administering at least one high voltage, short duration pulse to the tumor. The electroporation pulses may be administered at least 700V/cm for a duration of less than 1 millisecond. The intratumor treatments with electroporation may be administered in at least a two-treatment protocol with the time between treatments being about 7 days. The intratumor treatments with electroporation may be administered in a three-treatment protocol with a time of four days between the first and second treatments and a time of three days between the second and third treatments. It was found that the intratumor treatments using electroporation not only resulted in tumor regression but also induced an immune memory response which prevented the formation of new tumors.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: August 12, 2014
    Assignee: University of South Florida
    Inventors: Richard Heller, Loree C. Heller
  • Publication number: 20140193913
    Abstract: The methods and compositions described herein are based, in part, on the discovery of a stem cell state in human cells that resembles the morphology observed in murine-derived stem cells. Induction of such a state in human stem cells permits an increase in the efficiency of homologous recombination. Thus, the methods and compositions described herein relate to cells and methods for increasing the efficiency of homologous recombination in human stem cells.
    Type: Application
    Filed: August 16, 2013
    Publication date: July 10, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Niels Geijsen, Christa Buecker
  • Publication number: 20140189899
    Abstract: The present invention provides a new and improved method for producing hybrid silk and like fibers. The invention provides a method of sequence of use which has many advantages over prior art.
    Type: Application
    Filed: January 3, 2013
    Publication date: July 3, 2014
    Inventor: Sadia "Ross" Barrameda
  • Publication number: 20140127813
    Abstract: Systems, devices, and methods for delivering a biological material into an organelle of a cell are provided. In one aspect, for example, a method for introducing biological material into an organelle of a cell can include bringing into proximity outside of a cell a lance and a preselected biological material, charging the lance with a polarity and a charge sufficient to electrically associate the preselected biological material with a tip portion of the lance, and penetrating an outer portion of the cell with the lance and directing and inserting the lance into the cell but outside of the organelle. The method can further include discharging the lance to release at least a portion of the biological material, charging the lance with an opposite polarity and charge sufficient to electrophoretically drive at least a portion of the biological material into the organelle, and withdrawing the lance from the cell.
    Type: Application
    Filed: October 18, 2013
    Publication date: May 8, 2014
    Applicant: Brigham Young University
    Inventors: Quentin T. Aten, Regis A. David, Sandra H. Burnett, Brian D. Jensen, Larry L. Howell
  • Patent number: 8692192
    Abstract: The present invention relates generally to mass spectrometry. The present invention relates more particularly to methods and systems for use in mass spectrometric identification of a variety of analytes, including high molecular weight species such as proteins. One embodiment of the invention is a method for analyzing an analyte. The method includes nebulizing a suspension of the analyte in a solvent with a surface acoustic wave transducer; and performing mass spectrometry on the nebulized suspension. The surface acoustic wave transducer can be used, for example, to transfer non-volatile peptides and proteins (as well as other analyztes, such as oligonucleotides and polymers) to the gas phase at atmospheric pressure. Nebulization using surface acoustic waves can be conducted in a discontinuous or pulsed mode, similar to that used in MALDI, or in a continuous mode, as in ESI.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: April 8, 2014
    Assignee: University of Washington through its Center for Commercialization
    Inventors: David R. Goodlett, Scott R. Heron, Jon Cooper
  • Patent number: 8673623
    Abstract: An apparatus for performing magnetic electroporation is disclosed. A required electric field for electroporation is generated using a pulsed magnetic field through a closed magnetic yoke, such as a toroid, placed in a flow path of a fluid medium to be processed. The fluid medium flows through the orifice of the magnetic yoke, with the fluid medium flowing through and around the yoke. The required power to send a maximum flux through the magnetic yoke is less than the required power in a conventional apparatus for performing electroporation.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: March 18, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventor: Kent Davey
  • Publication number: 20140057355
    Abstract: The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.
    Type: Application
    Filed: March 11, 2013
    Publication date: February 27, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Junying Yu
  • Publication number: 20140017213
    Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.
    Type: Application
    Filed: May 24, 2013
    Publication date: January 16, 2014
    Inventors: Linhong Li, Madhusudan V. Peshwa
  • Patent number: 8617533
    Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: December 31, 2013
    Assignee: AlphaVax, Inc.
    Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
  • Patent number: 8580544
    Abstract: The invention relates to an apparatus for introducing a biological material, a method of introducing a biological material, and a magnetic support for introducing a biological material with the object of providing an apparatus for introducing a biological material, a method of introducing a biological material, and a magnetic support for introducing a biological material whereby a biological material can be efficiently introduced into a host. The invention comprises: one or more packing units in which a mixture solution containing a large number of magnetic supports carrying a biological material to be introduced into a host such as cells upon using, together with a large number of the hosts in a liquid is pooled; and an introduction treatment unit in which a magnetic force affecting the inside of the packing unit is controlled so as to move the magnetic supports relatively with respect to the host so that the biological material can be introduced into the host.
    Type: Grant
    Filed: October 16, 2003
    Date of Patent: November 12, 2013
    Assignees: Universal Bio Research Co. Ltd.
    Inventors: Hideji Tajima, Yoshiro Okami
  • Publication number: 20130280750
    Abstract: The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.
    Type: Application
    Filed: April 19, 2013
    Publication date: October 24, 2013
    Applicant: BIOLAMINA AB
    Inventors: Karl Tryggvason, Karl Kristian Tryggvason, Anna Domogatskaya
  • Patent number: 8551780
    Abstract: The subject invention concerns an electroporation buffer that allows for enhanced transfection efficiency and cell viability of cells during application of an electric current. Buffers of the invention provide for maximum transfer of target particles into cells while maintaining the health and growth potential of the cell population. Compositions of the invention comprise electroporation buffers of approximately physiological ionic strength and pH, and having serum or purified proteins, such as serum albumin, added thereto. The subject invention is suitable for use with any cell type. The subject invention also concerns methods of electroporation using an electroporation buffer of the invention.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: October 8, 2013
    Assignees: H. Lee Moffitt Cancer Center & Research Institute, Inc., University of South Florida, Proteacel, LLC
    Inventors: Deepak Kumar Agrawal, Warren Jackson Pledger, Jonathan A. Kluft, Asha Agrawal
  • Patent number: 8513000
    Abstract: Transfecting biology cells with nucleic acid molecules (DNA, siRNA) is an essential prerequisite in elucidating how genes function in complex cellular context and how their activities could be modulated for therapeutic intervention. Traditionally studies are carried out on a low throughput gene-by-gene scale, which has created a huge bottleneck in functional genomic study and drug discovery. Development of high-throughput cell transfection technology will permit functional analysis of massive number of genes and how their activities could be modulated by chemical or biological entities inside cells. This invention describes design, construction of device and apparatus for high throughput effective cell transfection. Procedures and protocols for using the device and apparatus are also described in the application. Novel methods of using the device in cell-based assays are also disclosed.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: August 20, 2013
    Assignee: Rational Biotechnology, Inc.
    Inventor: Yong Huang
  • Publication number: 20130195900
    Abstract: The present invention relates to a method of identifying a target antigen of T cells comprising (a) contacting (aa) cells expressing (i) a functional T cell receptor complex comprising predefined matching T cell receptor ? and ? chains; and (ii) a read-out system for T cell activation; with (ab) antigen-presenting cells carrying (iii) peptide libraries encoded by randomised nucleic acid sequences; and (iv) MHC molecules recognised by the T cell receptor of (i); (b) assessing T cell activation using said read-out system; (c) isolating antigen-presenting cells that are in contact with the cells in which the read-out system indicates T cell activation; (d) identifying the target antigen or the nucleic acid molecule encoding said target antigen.
    Type: Application
    Filed: August 5, 2011
    Publication date: August 1, 2013
    Applicant: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN
    Inventors: Klaus Dornmair, Reinhard Hohlfeld, Jorg Prinz, Katherina Siewert, Song-Min Kim
  • Publication number: 20130184332
    Abstract: The present invention refers to the construction of cloning vectors containing the max gene. Especially, the present invention refers to the introduction of cloning vectors containing the max gene in cells using transport vectors. In addition, the presence of cloning vectors containing the max gene in cells allows the differential expression of the max gene in the same cells. In addition, the present invention refers to a method of gene therapy in which the differential expression of the max gene has cytoprotective activity, especially neuroprotective activity, and is capable of application to medical and veterinary therapeutics of neurodegenerative conditions.
    Type: Application
    Filed: November 21, 2012
    Publication date: July 18, 2013
    Applicant: Universidade Federal Do Rio De Janeiro
    Inventor: Universidade Federal Do Rio De Janeiro
  • Publication number: 20130177988
    Abstract: Systems, devices, and methods for delivering a biological material into an organelle of a cell are provided. In one aspect, for example, a method for introducing biological material into an organelle of a cell can include bringing into proximity outside of a cell a lance and a preselected biological material, charging the lance with a polarity and a charge sufficient to electrically associate the preselected biological material with a tip portion of the lance, and penetrating an outer portion of the cell with the lance and directing and inserting the lance into the cell but outside of the organelle. The method can further include discharging the lance to release at least a portion of the biological material, charging the lance with an opposite polarity and charge sufficient to electrophoretically drive at least a portion of the biological material into the organelle, and withdrawing the lance from the cell.
    Type: Application
    Filed: November 19, 2012
    Publication date: July 11, 2013
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventor: Brigham Young University
  • Publication number: 20130157304
    Abstract: A method for preparing neoplastically transformed cells from human-derived cells, including the step of introducing human telomerase catalytic subunit (hTERT) gene, SV40 small T antigen (SV40ST) gene, and an antisense oligonucleotide derived from human 28S rRNA into the human-derived cells. The method for preparing neoplastically transformed cells from human-derived cells can be utilized when a variety of human normal cells are induced to be neoplastically transformed in order to elucidate cancer onset mechanisms, so that the method can be effectively utilized in search of target molecules for a new medicament.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 20, 2013
    Applicant: TRDIGM & Co., Ltd.
    Inventors: TRDIGM & Co., Ltd., Munesato Hamada
  • Patent number: 8465955
    Abstract: Described are methods for electrical treatment of biological cells, in particular using electrical field pulses, involving the steps: arrangement of the cells (1) on apertures (2) of a solid planar carrier element (3) which divides a measuring chamber (10) into two compartments (11, 12); and temporary formation of an electrical treatment field which permeates the cells, wherein an alternating-current impedance measurement takes place on the carrier element (3), and from the result of the alternating-current impedance measurement, a degree of coverage of the carrier element and/or healing of the cells after electrical treatment are/is acquired. Also described are devices for implementing the methods.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: June 18, 2013
    Assignee: Eppendorf AG
    Inventors: Ulrich Zimmermann, Vladimir Sukhorukov, Kurt Lucas
  • Patent number: 8450112
    Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: May 28, 2013
    Assignee: Maxcyte, Inc.
    Inventors: Linhong Li, Madhusudan V. Peshwa
  • Publication number: 20130130386
    Abstract: Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.
    Type: Application
    Filed: September 19, 2012
    Publication date: May 23, 2013
    Inventors: Dongsu PARK, David Spencer, Natalia Lapteva
  • Publication number: 20130122592
    Abstract: Provided is a method for transferring an extraneous gene by an electroporation technique, which is applicable to a wide range of animal cells and is extremely remarkably improved in viability and gene transferring rate. Also provided is a method for transferring an extraneous gene by an electroporation technique with high viability and gene transferring rate even in the case where no specialized transferring buffer is used. Also provided are: a method for transferring an extraneous gene by an electroporation technique, which is remarkably improved in viability and gene transferring rate, the method including continuously applying, to an animal cell, a first electric pulse (strong electric pulse) and a second electric pulse (weak electric pulse) under specific conditions; and a method for transferring an extraneous gene by an electroporation technique, in which a liquid medium capable of being used for culturing of the animal cell is used as a transferring buffer.
    Type: Application
    Filed: January 12, 2011
    Publication date: May 16, 2013
    Applicant: NEPA GENE CO., LTD.
    Inventors: Yasuhiko Hayakawa, Kiyoshi Hayakawa